Metropolitan Life Insurance CO Savara Inc Transaction History

Metropolitan Life Insurance CO

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$4.19 - $5.59 $7,286 - $9,721	-1,739 Reduced 32.56%	3,602 $17,000
Q3 2023 Nov 14, 2023	BUY	$2.97 - $3.88 $3,385 - $4,423	1,140 Added 27.14%	5,341 $20,000
Q2 2023 Aug 10, 2023	BUY	$1.69 - $3.24 $7,099 - $13,611	4,201 New	4,201 $13,000
Q2 2019 Jul 12, 2023	BUY	$2.37 - $11.7 $26,908 - $132,841	11,354 New	11,354 $26.9 Million
Q2 2019 Aug 14, 2019	SELL	$2.37 - $11.7 $26,908 - $132,841	-11,354 Closed	0 $0
Q1 2019 Jul 13, 2023	BUY	$6.71 - $8.6 $76,185 - $97,644	11,354 New	11,354 $83,000
Q1 2019 Mar 30, 2023	BUY	$6.71 - $8.6 $76,185 - $97,644	11,354 New	11,354 $83,000
Q1 2019 May 16, 2019	BUY	$6.71 - $8.6 $37,529 - $48,099	5,593 Added 97.08%	11,354 $83,000
Q1 2019 May 15, 2019	BUY	$6.71 - $8.6 $38,656 - $49,544	5,761 New	5,761 $138,000
Q4 2018 Feb 14, 2019	SELL	$6.27 - $10.92 $12,652 - $22,036	-2,018 Closed	0 $0
Q3 2018 Jul 13, 2023	BUY	$10.49 - $12.87 $96,654 - $118,584	9,214 New	9,214 $103 Million
Q3 2018 Nov 14, 2018	SELL	$10.49 - $12.87 $75,486 - $92,612	-7,196 Reduced 78.1%	2,018 $23,000
Q2 2018 Aug 15, 2018	BUY	$8.55 - $13.76 $78,779 - $126,784	9,214 New	9,214 $0

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $377M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.